MaaT Pharma SA (EPA:MAAT)
France flag France · Delayed Price · Currency is EUR
1.010
-0.020 (-1.94%)
Oct 2, 2026, 5:35 PM CET

MaaT Pharma Statistics

Total Valuation

MaaT Pharma has a market cap or net worth of EUR 19.03 million. The enterprise value is 11.61 million.

Market Cap19.03M
Enterprise Value 11.61M

Important Dates

The last earnings date was Tuesday, September 29, 2026.

Earnings Date Sep 29, 2026
Ex-Dividend Date n/a

Share Statistics

MaaT Pharma has 18.84 million shares outstanding.

Current Share Class 18.84M
Shares Outstanding 18.84M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 1.42%
Owned by Institutions (%) 20.00%
Float 11.04M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 5.99
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.65
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

Current Ratio n/a
Quick Ratio n/a
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -20.73

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) n/a
Return on Capital Employed (ROCE) n/a
Weighted Average Cost of Capital (WACC) 6.51%
Revenue Per Employee 56,714
Profits Per Employee -612,625
Employee Count59
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -75.72% in the last 52 weeks. The beta is 0.41, so MaaT Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.41
52-Week Price Change -75.72%
50-Day Moving Average 2.44
200-Day Moving Average 4.50
Relative Strength Index (RSI) 28.84
Average Volume (20 Days) 179,578

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, MaaT Pharma had revenue of EUR 3.18 million and -34.31 million in losses.

Revenue3.18M
Gross Profit 2.13M
Operating Income -33.98M
Pretax Income -34.31M
Net Income -34.31M
EBITDA -33.60M
EBIT -33.98M
Earnings Per Share (EPS) n/a
Full Income Statement

Balance Sheet

Cash & Cash Equivalents n/a
Total Debt n/a
Net Cash n/a
Net Cash Per Share n/a
Equity (Book Value) n/a
Book Value Per Share n/a
Working Capital n/a
Full Balance Sheet

Cash Flow

Operating Cash Flow n/a
Capital Expenditures -453,000
Depreciation & Amortization 380,000
Net Borrowing n/a
Free Cash Flow -16.00M
FCF Per Share -0.85
Full Cash Flow Statement

Margins

Gross Margin 67.16%
Operating Margin -1,070.03%
Pretax Margin -1,080.20%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

MaaT Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -180.26%
FCF Yield -84.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Analyst Forecast

The average price target for MaaT Pharma is 6.50, which is 543.56% higher than the current price. The consensus rating is "Buy".

Price Target 6.50
Price Target Difference 543.56%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (3Y) 117.55%
EPS Growth Forecast (3Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1